Get the Stockscreener App
1.45
4.32%
0.06
Citius Oncology Inc stock is traded at $1.45, with a volume of 1.31M.
It is up +4.32% in the last 24 hours and up +60.42% over the past month.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
See More
Previous Close:
$1.39
Open:
$1.33
24h Volume:
1.31M
Relative Volume:
0.91
Market Cap:
$91.59M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+13.28%
1M Performance:
+60.42%
6M Performance:
+30.63%
1Y Performance:
+0.00%
1-Day Range:
$1.23
$1.47
1-Week Range:
$1.2009
$1.52
52-Week Range:
$0.5506
$2.87
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.45 | 91.59M | 0 | 0 | 0 | 0.00 |
|
RGC
Regencell Bioscience Holdings Ltd
|
78.00 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
161.67 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.50 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.89 | 47.60B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.89 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
Citius Oncology On Track to Launch Lymphir in US in H2 - marketscreener.com
Citius Oncology prepares for lymphoma treatment launch in 2025 - Investing.com
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 - StreetInsider
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - The Victoria Advocate
Citadel Advisors LLC Makes New $26,000 Investment in Citius Oncology, Inc. (NASDAQ:CTOR) - Defense World
After Major Oncology Conference, All Eyes Turn to Industry Innovation - Cantech Letter
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - Longview News-Journal
Citius Pharmaceuticals Secures $15.8M Strategic Financing: LYMPHIR Commercial Launch Gets Green Light - Stock Titan
Citius Oncology partners with Cardinal Health for LYMPHIR distribution By Investing.com - Investing.com South Africa
Citius Oncology Enters Into Distribution Services Agreement With Cardinal Health - marketscreener.com
Citius Oncology Signs US Distribution Deal With Cardinal Health for Lymphir - marketscreener.com
Cardinal Health (CAH) Partners with Citius Oncology for LYMPHIR Distribution | CAH Stock News - GuruFocus
Citius Oncology Inks Distribution Services Agreement With Cardinal Health For LYMPHIR - Nasdaq
Citius Oncology stock soars on distribution deal By Investing.com - Investing.com South Africa
Citius Oncology stock soars on distribution deal - Investing.com
Citius Oncology partners with Cardinal Health for LYMPHIR distribution - Investing.com
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health | CTXR Stock News - GuruFocus
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health - Yahoo Finance
Citius Oncology (NASDAQ:CTOR) Trading Up 3.4% – Here’s Why - Defense World
This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Maxim Downgrades Citius Oncology to Hold From Buy - marketscreener.com
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Laun - GuruFocus
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Launch | CTXR Stock News - GuruFocus
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future - Yahoo Finance
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | CTXR Stock News - GuruFocus
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - PR Newswire
Citius Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus
US Stocks Dip As Investors Eye Trump's Tariff Announcements - Finimize
Citius Oncology IncReceives Nasdaq Notice For Bid Price Non-ComplianceSEC Filing - marketscreener.com
Citius Oncology (NASDAQ:CTOR) Trading 6.3% Higher – Still a Buy? - Defense World
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - Longview News-Journal
Citius Oncology Inc (NASDAQ: CTOR) Is On The Fall - stocksregister.com
Citius Pharma secures $2 million in stock offering By Investing.com - Investing.com South Africa
Citius Pharma secures $2 million in stock offering - Investing.com India
Citius Oncology (NASDAQ:CTOR) Shares Up 39.8% – Still a Buy? - Defense World
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
3 Penny Stocks to Watch Now, 4/1/25 - TipRanks
Why Citius Oncology Inc. Stock Spiked Over 7%? - timothysykes.com
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
IFP Advisors Inc Has $26,000 Stock Position in Citius Oncology, Inc. (NASDAQ:CTOR) - Defense World
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financia - GuruFocus.com
Citius Oncology Inc Stock (CTOR) Financials Data
There is no financial data for Citius Oncology Inc (CTOR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):